API | gemtuzumab ozogamicin

gemtuzumab ozogamicin (mylotarg) Report issue

Biologics mAb ADC Orphan Drug ^FDA Approved ^FDA Accelerated Approval ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW

Now

Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is an antibody-drug conjugate that is used to treat acute myeloid leukemia. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

gemtuzumab ozogamicin

gemtuzumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Myeloid cell surface antigen CD33 (Homo sapiens) ^UniProt
- Myeloid cell surface antigen CD33 (Homo sapiens) ^UniProt
Multi-specific: No
Payload: calicheamicin
Black Box: Yes
Availability: Missing data
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$6483.4800 - $8327.0400

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

cdp-771 | cma 676 | cma-676 | cmc-676 | gemtuzumab | gemtuzumab ozogamicin | gemtuzumab-ozogamicin | gemtuzumab ozogamycin | mylotarg | way-cma-676

Organizations (86)

Research & Development (85)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (21)

Approved Indications (2)

Leukemia, Myeloid

Leukemia, Myeloid, Acute (approved 2000)

Experimental Indications - Clinical Trial Phases 1-4 (21)

Bone Marrow Cells (Phase 2)

Electrocardiography (Phase 4)

Infusions, Intravenous (Phase 4)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)

Leukemia, Monocytic, Acute (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 4)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Leukemia, Myelomonocytic, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Early Phase 1)

Leukemia, Myelomonocytic, Juvenile (Phase 1)

Leukemia, Promyelocytic, Acute (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 2)

Pharmacokinetics (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Safety (Phase 4)

Sarcoma, Myeloid (Phase 2)

Transplantation, Homologous (Phase 1/Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 96
# of Trial Organizations: 85

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue